Results 21 to 30 of about 2,162 (171)

A comprehensive review of remimazolam for sedation  [PDF]

Health Psychology Research, 2021
Benzodiazepines are one of the most commonly used medications in the field of anesthesia. They offer excellent anxiolytic and amnestic properties ideal for the perioperative period when patient anxiety is understandably heightened. Remimazolam has presented a favorable alternative to some of the common intravenous anesthetic agents used given its fast ...
Nazir Noor, Rhorer Legendre, Alexandra Cloutet, Ahish Chitneni, Giustino Varrassi, Alan D. Kaye   +5 more
openaire   +3 more sources

Clinical Application and Research Progress of Remimazolam for Pediatric Patients

Drug Design, Development and Therapy
Chen Bai, Mingcan Xu, Yan Guo, Yanwu Jin, Xin Zhao Department of Anesthesiology, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, 250033, People’s Republic of ChinaCorrespondence: Yanwu Jin; Xin Zhao, Department of ...
Bai C, Xu M, Guo Y, Jin Y, Zhao X
doaj   +2 more sources

Remimazolam Has Low Oral Bioavailability and No Potential for Misuse in Drug-Facilitated Sexual Assaults, with or Without Alcohol: Results from Two Randomised Clinical Trials

Drugs in R&D, 2020
Background and Objectives Remimazolam is a new ultra-short-acting benzodiazepine currently being developed for intravenous use in procedural sedation, general anaesthesia, and intensive care unit sedation.
Marija Pesic, Thomas Stöhr, Joachim Ossig, Keith Borkett, Martin Donsbach, Van-Anh Dao, Lynn Webster, Frank Schippers   +7 more
doaj   +1 more source

Total intravenous anesthesia management with simultaneous use of remimazolam and propofol: A case series of three patients

SAGE Open Medical Case Reports, 2023
Remimazolam is an ultra-short-acting benzodiazepine anesthetic agent. Because of pharmacodynamic interactions in the sedation effect between benzodiazepines and propofol, the combination of remimazolam and propofol may allow for a dose reduction of each ...
Yuki Watanabe, Shinju Obara, Satoki Inoue   +2 more
doaj   +1 more source

Remimazolam Anesthesia for MitraClip Implantation in a Patient with Advanced Heart Failure

Case Reports in Anesthesiology, 2021
Remimazolam, a novel and ultrashort-acting benzodiazepine, has been available for general anesthesia in Japan. The administration of remimazolam does not induce injection pain, has been reported to have less cardiovascular depressant effects during ...
Tomoe Satoh, Noriaki Nishihara, Yasuaki Sawashita, Sho Ohno, Naoyuki Hirata, Michiaki Yamakage   +5 more
doaj   +1 more source

Remimazolam for anaesthesia or sedation [PDF]

Current Opinion in Anaesthesiology, 2020
Purpose of review Anaesthesia and sedation are ubiquitous in contemporary medical practice. Developments in anaesthetic pharmacology are targeted on reducing physiological disturbance whilst maintaining or improving titrateability, recovery profile and patient experience.
J Robert, Sneyd, Ann E, Rigby-Jones
openaire   +2 more sources

Three cases of difficulty in achieving definitive loss of consciousness with remimazolam

JA Clinical Reports, 2022
Background Remimazolam is a novel, ultra-short-acting benzodiazepine used for general anesthesia. Because remimazolam is an emerging drug, the tolerance to remimazolam in benzodiazepine-taking patients has been unclear.
Mao Miyanishi, Toru Yaguramaki, Yasuhiro Maehara, Osamu Nagata   +3 more
doaj   +1 more source

Comparison of postoperative nausea and vomiting between remimazolam and propofol: a propensity score-matched, retrospective, observational, single-center cohort study [PDF]

Korean Journal of Anesthesiology, 2023
Background Remimazolam is a novel ultrashort-acting benzodiazepine that has recently become available for general anesthesia. However, the incidence of postoperative nausea and vomiting (PONV) associated with remimazolam remains unknown.
Yuji Suzuki, Shingo Kawashima, Hiroshi Makino, Matsuyuki Doi, Yoshiki Nakajima   +4 more
doaj   +1 more source

Remimazolam anesthesia for cardiac surgery with cardiopulmonary bypass: a case report

JA Clinical Reports, 2021
Background Remimazolam has less cardiovascular depressant effects than propofol in non-cardiac surgical patients. However, the efficacy and safety of remimazolam in cardiac surgery with cardiopulmonary bypass (CPB) have not been reported.
Kota Saito, Sho Ohno, Makishi Maeda, Naoyuki Hirata, Michiaki Yamakage   +4 more
doaj   +1 more source

Effects of remimazolam versus dexmedetomidine on recovery after transcatheter aortic valve replacement under monitored anesthesia care: a propensity score-matched, non-inferiority study [PDF]

Korean Journal of Anesthesiology
Background Minimalist transcatheter aortic valve replacement (TAVR) under monitored anesthesia care (MAC) emphasizes early recovery. Remimazolam is a novel benzodiazepine with a short recovery time.
Ji-Hyeon Kim, Jae-Sik Nam, Wan-Woo Seo, Kyung-Woon Joung, Ji-Hyun Chin, Wook-Jong Kim, Dae-Kee Choi, In-Cheol Choi   +7 more
doaj   +1 more source